Organization
ChangSha TaiHe Hospital
3 abstracts
Abstract
First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.Org: ChangSha TaiHe Hospital, Shulan (Hangzhou) Hospital, Deyang People's Hospital, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Anhui Provincal Hospital,
Abstract
First-in-human study of ZG005, a dual specific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors.Org: Jilin Cancer Hospital, Changchun, China, Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun, China, Shulan (Hangzhou) Hospital, Hangzhou, China,
Abstract
First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Hospital of China Medical University, Shenyang, China, Lung & Gastrointestinal Oncology Department,